Pfizer has stopped work on the obesity drug Danuglipron, according to bloomberg.com. The reason is that a serious liver-related adverse effect was identified in one participant during clinical trials.
With this decision, the company may halt competition with market leaders in weight-loss drugs — Novo Nordisk and Eli Lilly. Pfizer will not conduct the final phase of trials and will focus on early-stage solutions for obesity.
According to Bloomberg, Pfizer, which made significant profits during the COVID-19 pandemic, was looking to actively engage in the weight loss market. This sector is expected to reach $130 billion by 2030.
